Eucrisa (Crisaborole) – Atopic Dermatitis | DengYueMed

Eucrisa Application Scope

Eucrisa is a non-steroidal, topical phosphodiesterase-4 (PDE-4) inhibitor used to treat mild to moderate atopic dermatitis.

Characteristics

• Ingredients: Acalabrutinib

• Properties:

  • White to off-white topical ointment

  • Mechanism: PDE-4 inhibition reduces inflammatory cytokines

• Packaging Specification: Laminated tubes of 60 g or 100 g ointment

• Storage:

  • Store at controlled room temperature (20–25 °C; 15–30 °C excursions allowed)

  • Keep the tube tightly closed

• Expiry Date: Date indicated on packaging

• Executive Standard: FDA-approved label, Health Canada monograph version

• Approval Number: FDA NDA 207695 (initial approval December 2016)

• Date of Revision: U.S. prescribing info revised April 2023

• Manufacturer: Pfizer Inc.

Guidelines for the Use of Eucrisa

• Dosage and Administration:

  • Apply a thin layer to affected areas twice daily

  • Once symptoms improve, dosing may be reduced to once daily

  • For topical use only—not for ophthalmic, oral, or intravaginal use

• Adverse Reactions:

  • Most common:

    • Application site pain (burning or stinging) in ≈4% of users vs. ≈1% of vehicle users

  • Less common (<1%):

    • Contact urticaria and allergic contact dermatitis

  • Post-marketing:

    • Includes allergic contact dermatitis

• Contraindications: Known hypersensitivity to crisaborole or any component

• Precautions:

  • Discontinue immediately if hypersensitivity occurs (e.g., swelling, severe pruritus)

  • Safety in infants under 3 months has not been established

  • Use caution during pregnancy and breastfeeding

  • Animal studies showed no fetal harm at high doses

Eucrisa Interactions

• Drug Interactions:

  • In vitro data suggest that crisaborole does not inhibit major CYP enzymes

  • Clinically relevant interactions are unlikely

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.